Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors.


Journal

Bosnian journal of basic medical sciences
ISSN: 1840-4812
Titre abrégé: Bosn J Basic Med Sci
Pays: Bosnia and Herzegovina
ID NLM: 101200947

Informations de publication

Date de publication:
03 Aug 2020
Historique:
received: 01 02 2020
accepted: 04 02 2020
pubmed: 6 2 2020
medline: 19 5 2021
entrez: 6 2 2020
Statut: epublish

Résumé

The two most commonly used immunohistochemical markers for neuroendocrine cells and their tumors are chromogranin A (CgA) and synaptophysin (SPY). CgA is a marker for neuroendocrine secretory granules of four pancreatic hormones and gastrin while SPY is a marker for synaptic vesicles in neuroendocrine cells, which release classic neurotransmitters such as acetylcholine and others. CgA is involved in synthesis and secretion of peptide hormones through exocytosis while the function of SPY is elusive. Thirty-five pancreatic neuroendocrine tumors (Pan-NETs) were studied, consisting of 14 insulinomas, 8 gastrinomas, 2 glucagonomas, 6 pancreatic polypeptidomas and 5 non-functioning tumors, and were immunostained for four pancreatic hormones, gastrin, CgA, and SPY. Majority of Pan-NETs were less immunostained for the endocrine hormones and CgA than the normal pancreatic endocrine cells. CgA immunostaining mostly correlates with each hormone staining in non-β-cell tumors, while SPY immunostaining recognizes endocrine cells diffusely in the cytoplasm. CgA immunostaining is less in insulinomas than in non-β-cell tumors, and CgA immunostaining may distinguish CgA-weaker insulinomas from CgA-stronger non-β-cell tumors. CgA immunostaining may be used as an independent marker for biological aggressiveness in non-β-cell Pan-NETs. The serum CgA levels are higher in subjects harboring non-β-cell tumors than those harboring insulinomas, and the serum CgA elevates in parallel to the increasing metastatic tumor mass. Thus, CgA positive immunostaining in Pan-NETs correlates with the elevated serum levels of CgA for diagnosing CgA-positive non-β-cell Pan-NETs and the increasing serum CgA levels indicate increasing metastatic tumor mass.

Identifiants

pubmed: 32020844
doi: 10.17305/bjbms.2020.4632
pmc: PMC7416176
doi:

Substances chimiques

Biomarkers, Tumor 0
Chromogranin A 0
Synaptophysin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

336-346

Références

Arch Pathol Lab Med. 1990 Jul;114(7):700-4
pubmed: 1694655
Eur J Clin Invest. 1998 Jun;28(6):431-40
pubmed: 9693933
J Histochem Cytochem. 1986 Dec;34(12):1673-82
pubmed: 2878021
Am J Pathol. 1983 Nov;113(2):134-42
pubmed: 6314815
Endocr Rev. 2011 Dec;32(6):755-97
pubmed: 21862681
N Engl J Med. 2003 Mar 20;348(12):1134-49
pubmed: 12646671
Ann Intern Med. 1998 Sep 15;129(6):484-94
pubmed: 9735087
Int J Biol Markers. 2004 Oct-Dec;19(4):295-304
pubmed: 15646836
World J Methodol. 2017 Mar 26;7(1):9-15
pubmed: 28396845
Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):737-53
pubmed: 23582916
Am J Surg Pathol. 1996 Nov;20(11):1378-84
pubmed: 8898842
Arch Pathol Lab Med. 2006 Jul;130(7):963-6
pubmed: 16831051
Neuroendocrinology. 2006;84(3):173-82
pubmed: 17312377
Diabetes. 1996 Feb;45(2):223-41
pubmed: 8549869
Pathol Int. 2002 Jul;52(7):425-32
pubmed: 12167099
Arch Med Sci. 2016 Feb 1;12(1):1-9
pubmed: 26925113
Ann N Y Acad Sci. 2004 Apr;1014:13-27
pubmed: 15153416
Mod Pathol. 1997 Jan;10(1):47-54
pubmed: 9021726
Annu Rev Cell Biol. 1987;3:243-93
pubmed: 3318877
Eur J Cancer. 2012 Aug;48(12):1766-73
pubmed: 22133573
Sci Rep. 2015 Sep 03;5:13659
pubmed: 26333660
Am J Surg. 1984 Jan;147(1):25-31
pubmed: 6691547
Mod Pathol. 2007 Feb;20 Suppl 1:S94-112
pubmed: 17486055
J Clin Invest. 1993 Nov;92(5):2092-8
pubmed: 8227324
Cancer. 1985 Oct 1;56(7):1649-57
pubmed: 2992743
Am J Surg Pathol. 1984 Aug;8(8):607-14
pubmed: 6205601
Clin Gastroenterol Hepatol. 2008 Jul;6(7):820-7
pubmed: 18547872
Prog Brain Res. 1995;105:79-85
pubmed: 7568899
Mol Endocrinol. 2008 Aug;22(8):1935-49
pubmed: 18483175
Diabetes. 1974 Jun;23(6):517-24
pubmed: 4600579
Oncologist. 2009 May;14(5):456-67
pubmed: 19411317
Ann Surg Oncol. 2010 Sep;17(9):2427-43
pubmed: 20217257
Medicine (Baltimore). 2014 Dec;93(27):e247
pubmed: 25501094
Endocr Pathol. 2003 Winter;14(4):293-301
pubmed: 14739487
Hum Pathol. 1987 Apr;18(4):367-74
pubmed: 3549533
Clin Cancer Res. 2008 Dec 1;14(23):7798-803
pubmed: 19047107
Ann Surg. 1981 Dec;194(6):692-7
pubmed: 7030236
J Clin Endocrinol Metab. 1997 Aug;82(8):2622-8
pubmed: 9253344
Arch Pathol Lab Med. 2015 Jun;139(6):750-6
pubmed: 26030244
Mod Pathol. 2000 Apr;13(4):389-95
pubmed: 10786804
Differentiation. 1994 May;56(3):163-71
pubmed: 8034131
Cancer. 1986 Jan 1;57(1):129-33
pubmed: 3000569
Cell. 2001 Aug 24;106(4):499-509
pubmed: 11525735
Gastroenterology. 1983 Jun;84(6):1524-32
pubmed: 6840481
Eur J Intern Med. 2008 Mar;19(2):99-103
pubmed: 18249304
Neuron. 1999 Nov;24(3):687-700
pubmed: 10595519
Neurochem Res. 1993 Jan;18(1):59-64
pubmed: 8464536
Endocr Connect. 2014 Apr 29;3(2):R45-54
pubmed: 24671122
Proc Natl Acad Sci U S A. 1982 Oct;79(19):6056-9
pubmed: 6821132
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2945-50
pubmed: 19202060
EMBO J. 2014 Apr 16;33(8):788-822
pubmed: 24596248
Scand J Gastroenterol. 2008 Jan;43(1):20-4
pubmed: 18938772
Cancer. 1999 Sep 1;86(5):858-65
pubmed: 10463986

Auteurs

Tatsuo Tomita (T)

Departments of Integrative Biosciences and Pathology, Oregon Health and Science University, Portland, Oregon, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH